Communiqués Omeros Corporation

Actions

OMER

US6821431029

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 09/10/2026			Varia. 5j.	Varia. 1 janv.
19,83 ^USD	+3,71 %		+6,56 %	+15,46 %

22/09	Principales hausses de la mi-séance	MT
22/09	L’action Omeros progresse après un relèvement de recommandation de Cantor Fitzgerald	MT

Communiqués

12/08	Omeros: Q2 Earnings Snapshot	AQ
12/08	Omeros Corporation Reports Second Quarter 2026 Financial Results	BU
10/08	Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026	BU
03/08	CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®	BU
26/06	Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA	BU
15/06	Omeros Announces Webcast Details for Annual Meeting of Shareholders	BU
13/05	Omeros: Q1 Earnings Snapshot	AQ
13/05	Omeros Corporation Reports First Quarter 2026 Financial Results	BU
11/05	Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026	BU
17/04	Omeros Corporation - CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA	AQ
16/04	CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)	BU
31/03	Omeros: Q4 Earnings Snapshot	AQ
31/03	Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results	BU
26/03	Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026	BU
21/03	Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment	BU
17/02	Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program	BU
27/01	Omeros Announces First Commercial Sales of YARTEMLEA®	BU
29/12	Omeros Announces New Date for YARTEMLEA(R) Approval Conference Call	AQ
27/12	Omeros Announces New Date for YARTEMLEA® Approval Conference Call	BU
24/12	FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA	BU
01/12	Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)	BU
13/11	Omeros: Q3 Earnings Snapshot	AQ
13/11	Omeros Corporation Reports Third Quarter 2025 Financial Results	BU
11/11	Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025	BU
16/10/25	Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group	BU